Legend Biotech’s Carvykti, a cell therapy for relapsed or lenalidomide-refractory multiple myeloma, demonstrated significant improvement in overall survival compared to standard therapies in a three-year follow-up study. The data presented at the International Myeloma Society Annual Meeting suggests that Carvykti could become a leading treatment option for patients after their first relapse.
Interius BioTherapeutics presents preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting demonstrating the safety and efficacy of its lead in vivo cell-specific gene medicine candidate, INT2104, for treating B-cell malignancies. INT2104 is a targeted lentiviral vector-based therapy that transduces T cells and NK cells upon intravenous administration, without requiring preconditioning chemotherapy. In vivo studies in humanized mice and cynomolgus macaques showed that a single intravenous administration of INT2104 resulted in sustained B cell depletion and antitumor activity. A GLP toxicology study established a favorable safety profile, providing support for clinical entry of INT2104 this year for B-cell malignancies.
Vertex Pharmaceuticals has partnered with TreeFrog Therapeutics to obtain an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-Stem. This collaboration aims to optimize the production of Vertex’s cell therapies for type 1 diabetes (T1D). TreeFrog’s technology is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. By scaling up TreeFrog’s process, Vertex will be able to generate large amounts of fully differentiated cells for its T1D therapies.
